???global.info.a_carregar???
Arlindo Rebelo Ferreira concluiu o Doutoramento em Medicina do Programa Doutoral do Centro Académico de Medicina de Lisboa (ramo de Medicina; ramo de Ciências Biomédicas; ramo de Ciências e Tecnologias da Saúde) pela Faculdade de Medicina da Universidade de Lisboa em 2020 e o Mestrado Integrado em Medicina em 2010 pela mesma Universidade. É assistente e investigador clínico na Fundação Champalimaud, tal como assistente convidado na Faculdade de Medicina da Universidade Católica Portuguesa. Publicou dezenas de artigos em revistas especializadas. É investigador principal de ensaio clínico com intervenção de iniciativa do investigador e co-investigador em vários outros ensaios clínicos.
Read full resume ↓
Identification

Personal identification

Full name
Arlindo Júlio Rebelo da Silva Ferreira

Citation names

  • Ferreira, Arlindo
  • Ferreira, Arlindo R

Author identifiers

Ciência ID
F112-254C-6DC4
ORCID iD
0000-0002-1567-9322
Google Scholar ID
hxmXfRcAAAAJ&hl

Email addresses

  • arlindoferreira@fundacaochampalimaud.pt (Professional)

Addresses

  • Fundação Champalimaud, 1400-038, Lisboa, Lisboa, Portugal (Professional)

Websites

Knowledge fields

  • Exact Sciences - Mathematics - Statistics and Probability
  • Medical and Health Sciences - Clinical Medicine - Oncology

Languages

Language Speaking Reading Writing Listening Peer-review
English Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Portuguese Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Spanish; Castilian Beginner (A1) Intermediate (B1) Beginner (A1) Beginner (A1)
French Beginner (A1) Beginner (A1) Beginner (A1) Beginner (A1)
Education
Degree Classification
2015/10/01 - 2020/10/28
Concluded
 Programa Doutoral do Centro Académico de Medicina de Lisboa (ramo de Medicina; ramo de Ciências Biomédicas; ramo de Ciências e Tecnologias da Saúde) (Doutoramento)
Major in Oncologia
Universidade de Lisboa Faculdade de Medicina, Portugal
"Adjuvant endocrine therapy for the treatment of early breast cancer: real world effectiveness, tolerability and adherence" (THESIS/DISSERTATION)
2015/02/01 - 2015/06/30
Concluded
 CORe: Credential of Readiness (Postgraduate Certificate)
Harvard Business School, United States
2012/03/01 - 2014/12/01
Concluded
 Double Master Degree in Clinical Research and Regulatory Affairs for Drugs, Biologics, and Medical Devices (Mestrado)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal

Northeastern University, United States
19
2013/12/15
Concluded
 Clinical Scholars Research Training I and II (Pós-Graduação)
Harvard Medical School, United States
"Não aplicável" (THESIS/DISSERTATION)
 Aprovado
2010
Concluded
 Mestrado Integrado em Medicina (Mestrado)
Universidade de Lisboa Faculdade de Medicina, Portugal
"Linfoma MALT do pulmão e anel de Waldeyer" (THESIS/DISSERTATION)
 17.07
Affiliation

Teaching in Higher Education

Category
Host institution 		Employer
2021/09/01 - Current Invited Assistant Professor (University Teacher) Universidade Católica Portuguesa - Faculdade de Medicina, Portugal

Other Careers

Category
Host institution 		Employer
2019/03/01 - Current Assistente (Pessoal da Saúde - Técnico Superior de Saúde - Psicologia Clínica) Fundação Champalimaud, Portugal

Others

Category
Host institution 		Employer
2013/01/01 - 2020/10/31 Investigador Clínico Instituto de Medicina Molecular, Portugal
2012/01/01 - 2018/11/30 Médico Interno de Oncologia Médica Centro Hospitalar Universitário Lisboa Norte EPE, Portugal
2011/01/01 - 2011/12/31 Médico Interno do Ano Comum Centro Hospitalar Universitário Lisboa Central EPE, Portugal
Projects

Grant

Designation Funders
2014/07 - 2016/12 HMSP-ICJ/0007/2013 - Junior Research and Career Development Award
HMSP-ICJ/0007/2013
 Fundação para a Ciência e a Tecnologia

Other

Designation Funders
2022/01/01 - Current Immunogenicity Profile of Neoadjuvant Keytruda in Combination with Anthracycline versus Carboplatin/Paclitaxel Containing Chemotherapy Regimen for The Treatment of Early-stage, TILs-Positive, Triple-Negative Breast CanceR – a phase II clinical trial (KeyPARTNER)
Ferreira (Ribeiro) 60956
Principal investigator
Fundação Champalimaud, Portugal
 Merck and Co Inc El Paso
Ongoing
Outputs

Publications

Journal article
  1. Pedro F. Gouveia; Joana Costa; Pedro Morgado; Ronald Kates; David Pinto; Carlos Mavioso; João Anacleto; et al. "Breast cancer surgery with augmented reality". The Breast (2021): https://doi.org/10.1016/j.breast.2021.01.004.
    10.1016/j.breast.2021.01.004
  2. Elise Martin; Antonio Di Meglio; Cecile Charles; Arlindo Ferreira; Arnauld Gbenou; Marine Blond; Benoit Fagnou; et al. "Use of mHealth to Increase Physical Activity Among Breast Cancer Survivors With Fatigue: Qualitative Exploration". JMIR Cancer (2021): https://doi.org/10.2196/23927.
    10.2196/23927
  3. Arlindo R. Ferreira; Sofia Ferreira; Matteo Lambertini; Christian Maurer; Samuel Martel; Luis Costa; Noam Ponde; Evandro de Azambuja. "Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial". European Journal of Cancer 144 (2021): 351-359. https://doi.org/10.1016/j.ejca.2020.11.023.
    10.1016/j.ejca.2020.11.023
  4. Mariana Brandão; Christian Maurer; Patricia Klarmann Ziegelmann; Noam F. Pondé; Arlindo Ferreira; Samuel Martel; Martine Piccart; et al. "Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis". ESMO Open 5 4 (2020): e000842-e000842. https://doi.org/10.1136/esmoopen-2020-000842.
    10.1136/esmoopen-2020-000842
  5. Soraia Lobo-Martins; Arlindo R. Ferreira; André Mansinho; Sandra Casimiro; Kim Leitzel; Suhail Ali; Allan Lipton; Luís Costa. "Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases". Cancers (2020): https://doi.org/10.3390/cancers12082034.
    10.3390/cancers12082034
  6. A.R. Ferreira; A. Di Meglio; B. Pistilli; A.S. Gbenou; M. El-Mouhebb; S. Dauchy; C. Charles; et al. "Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis". Annals of Oncology 30 11 (2019): 1784-1795. https://doi.org/10.1093/annonc/mdz298.
    10.1093/annonc/mdz298
  7. Otto Metzger-Filho; Arlindo R. Ferreira; Rinath Jeselsohn; William T. Barry; Deborah A. Dillon; Jane E. Brock; Ines Vaz-Luis; et al. "Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade". The Oncologist 24 7 (2019): e441-e449. https://doi.org/10.1634/theoncologist.2018-0363.
    10.1634/theoncologist.2018-0363
  8. Lambertini M; Campbell C; Gelber RD; Viale G; McCullough A; Hilbers F; Korde LA; et al. "Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.". Breast cancer research and treatment (2019): http://europepmc.org/abstract/med/31134488.
    10.1007/s10549-019-05284-y
  9. Loureiro, H.; Carrasquinha, E.; Alho, I.; Ferreira, A.R.; Costa, L.; Carvalho, A.M.; Vinga, S.. "Modelling cancer outcomes of bone metastatic patients: Combining survival data with N-Telopeptide of type i collagen (NTX) dynamics through joint models 01 Mathematical Sciences 0104 Statistics". BMC Medical Informatics and Decision Making 19 1 (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85060148696&partnerID=MN8TOARS.
    10.1186/s12911-018-0728-1
  10. Mansinho, A.; Ferreira, A.R.; Casimiro, S.; Alho, I.; Vendrell, I.; Costa, A.L.; Sousa, R.; et al. "Levels of circulating fibroblast growth factor 23 (FGF23) and prognosis in cancer patients with bone metastases". International Journal of Molecular Sciences 20 3 (2019): http://www.scopus.com/inward/record.url?eid=2-s2.0-85061233557&partnerID=MN8TOARS.
    10.3390/ijms20030695
  11. Vendrell, I.; Ferreira, A.R.; Abrunhosa-Branquinho, A.N.; Semedo, P.M.; Pulido, C.F.; Jorge, M.; De Pina, M.F.; Pinto, C.; Costa, L.. "Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer". Medicine (United States) 97 30 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85050865163&partnerID=MN8TOARS.
    10.1097/MD.0000000000011592
  12. Ferreira, A.R.; Metzger-Filho, O.; Sarmento, R.M.B.; Bines, J.. "Neoadjuvant treatment of stage IIB/III triple negative breast cancer with cyclophosphamide, doxorubicin, and Cisplatin (CAP Regimen): A single arm, single center Phase II study (GBECAM 2008/02)". Frontiers in Oncology 7 JAN (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85041227717&partnerID=MN8TOARS.
    10.3389/fonc.2017.00329
  13. Maurer, C.; Ferreira, A.R.; Martel, S.; Lambertini, M.; Pondé, N.; Aftimos, P.; de Azambuja, E.; Piccart, M.. "Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer". Breast 39 (2018): 14-18. http://www.scopus.com/inward/record.url?eid=2-s2.0-85042193786&partnerID=MN8TOARS.
    10.1016/j.breast.2018.02.027
  14. Ferreira, Arlindo. "Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.". Breast (Edinburgh, Scotland) (2017): http://europepmc.org/abstract/med/29161652.
    10.1016/j.breast.2017.11.004
  15. Ferreira, Arlindo. "Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.". Breast (Edinburgh, Scotland) (2017): http://europepmc.org/abstract/med/29131988.
    10.1016/j.breast.2017.11.003
  16. Ferreira, Arlindo. "Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.". Cancer treatment reviews (2017): http://europepmc.org/abstract/med/29108713.
    10.1016/j.ctrv.2017.09.009
  17. Ferreira, Arlindo. "Adjuvant zoledronic acid to treat breast cancer: not for all.". The Lancet. Oncology (2017): http://europepmc.org/abstract/med/29037985.
    10.1016/s1470-2045(17)30695-2
  18. Ferreira, Arlindo. "Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.". Annals of oncology : official journal of the European Society for Medical Oncology (2017): http://europepmc.org/abstract/med/29045555.
    10.1093/annonc/mdx639
  19. Ferreira AR; Bettencourt M; Alho I; Costa AL; Sousa AR; Mansinho A; Abreu C; et al. "Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases.". (2017): http://europepmc.org/abstract/med/28194325.
    10.1016/j.jbo.2017.01.002
  20. Lambertini, M.; Ferreira, A.R.; Di Meglio, A.; Poggio, F.; Puglisi, F.; Sottotetti, F.; Montemurro, F.; et al. "Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study". Clinical Breast Cancer 17 8 (2017): 601-610.e2. http://www.scopus.com/inward/record.url?eid=2-s2.0-85018989775&partnerID=MN8TOARS.
    10.1016/j.clbc.2017.04.002
  21. Pulido C; Vendrell I; Ferreira AR; Casimiro S; Mansinho A; Alho I; Costa L. "Bone metastasis risk factors in breast cancer.". (2017): http://europepmc.org/abstract/med/28194227.
    10.3332/ecancer.2017.715
  22. Costa, L.; Ferreira, A.R.. "Adjuvant zoledronic acid to treat breast cancer: not for all". The Lancet Oncology 18 11 (2017): 1437-1439. http://www.scopus.com/inward/record.url?eid=2-s2.0-85031317213&partnerID=MN8TOARS.
    10.1016/S1470-2045(17)30695-2
  23. Arlindo R. Ferreira; Ana Palha; Lurdes Correia; Pedro Filipe; Vasco Rodrigues; Luís Costa; Ana Miranda; et al. "Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study". The Breast 29 (2016): 68-73. http://dx.doi.org/10.1016/j.breast.2016.07.004.
    10.1016/j.breast.2016.07.004
  24. André Mansinho; Arlindo R Ferreira; Luís Costa. "Hypocalcemia in patients with metastatic bone disease treated with denosumab". Ann. Joint 1 (2016): 16-16. http://dx.doi.org/10.21037/aoj.2016.08.02.
    10.21037/aoj.2016.08.02
  25. Ferreira, Arlindo. "Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?". International Journal of Molecular Sciences (2016): http://www.mdpi.com/1422-0067/17/9/1415.
    10.3390/ijms17091415
  26. Arlindo Ferreira; Irina Alho; Inês Vendrell; Marta Melo; Raquel Brás; Ana Lúcia Costa; Ana Rita Sousa; et al. "The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases". Oncotarget (2016): http://dx.doi.org/10.18632/oncotarget.9356.
    10.18632/oncotarget.9356
  27. Rui Moura Coelho; João Miranda Lemos; Irina Alho; Duarte Valério; Arlindo R Ferreira; Luís Costa; Susana Vinga. "Dynamic modeling of bone metastasis, microenvironment and therapy". Journal of Theoretical Biology 391 (2016): 1-12. http://dx.doi.org/10.1016/j.jtbi.2015.11.024.
    10.1016/j.jtbi.2015.11.024
  28. Ferreira, A.R.; Alho, I.; Shan, N.; Matias, M.; Faria, M.; Casimiro, S.; Leitzel, K.; et al. "N-telopeptide of type I collagen long-term dynamics in breast cancer patients with bone metastases: Clinical outcomes and influence of extraskeletal metastases". Oncologist 21 12 (2016): 1418-1426. http://www.scopus.com/inward/record.url?eid=2-s2.0-85006753213&partnerID=MN8TOARS.
    10.1634/theoncologist.2015-0527
  29. Matteo Lambertini; Arlindo R Ferreira; Lucia Del Mastro; Romano Danesi; Paolo Pronzato. "Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors". Expert Opinion on Biological Therapy 15 12 (2015): 1799-1817. http://dx.doi.org/10.1517/14712598.2015.1101063.
    10.1517/14712598.2015.1101063
  30. Arlindo R Ferreira. "Treatment of early-stage HER2 breast cancer—an evolving field". ecancer 9 (2015): http://dx.doi.org/10.3332/ecancer.2015.523.
    10.3332/ecancer.2015.523
  31. Arlindo Ferreira; Irina Alho; Sandra Casimiro; Luís Costa. "Bone remodeling markers and bone metastases: From cancer research to clinical implications". BoneKEy Rep 4 (2015): 668-668. http://dx.doi.org/10.1038/bonekey.2015.35.
    10.1038/bonekey.2015.35
  32. Sargento-Freitas, J.; Laranjinha, I.; Galego, O.; Rebelo-Ferreira, A.; Moura, B.; Correia, M.; Silva, F.; et al. "Nocturnal blood pressure dipping in acute ischemic stroke". Acta Neurologica Scandinavica 132 5 (2015): 323-328. http://www.scopus.com/inward/record.url?eid=2-s2.0-84942869968&partnerID=MN8TOARS.
    10.1111/ane.12402
  33. Lambertini, M.; Ferreira, A.R.; Poggio, F.; Puglisi, F.; Bernardo, A.; Montemurro, F.; Poletto, E.; et al. "Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study". Oncologist 20 8 (2015): 880-889. http://www.scopus.com/inward/record.url?eid=2-s2.0-84940027287&partnerID=MN8TOARS.
    10.1634/theoncologist.2015-0020

Other

Other output
  1. Prostate Cancer. 2015. Arlindo R. Ferreira; André Abrunhosa-Branquinho; Inês Vendrell; António Quintela; Filomena Pina; Leonor Ribeiro. http://dx.doi.org/10.1007/978-3-319-21683-6_22.
    10.1007/978-3-319-21683-6_22
  2. Bone Metastases. 2015. Arlindo R. Ferreira; André Abrunhosa-Branquinho; Marília Jorge; Luís Costa; Inês Vaz-Luís. http://dx.doi.org/10.1007/978-3-319-21683-6_40.
    10.1007/978-3-319-21683-6_40
Distinctions

Other distinction

2014 Junior Research and Career Development Award - Harvard Medical School Portuguese Program
Fundação para a Ciência e a Tecnologia, Portugal